Novo Nordisk A/S (NVO): Today's Featured Drugs Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Novo Nordisk A/S ( NVO) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.6%. By the end of trading, Novo Nordisk A/S fell $3.13 (-1.7%) to $178.51 on average volume. Throughout the day, 431,348 shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 305,900 shares. The stock ranged in price between $177.81-$180.66 after having opened the day at $180.25 as compared to the previous trading day's close of $181.64. Other companies within the Drugs industry that declined today were: Aoxing Pharmaceutical Company ( AXN), down 20%, Opexa Therapeutics ( OPXA), down 14.9%, iBio ( IBIO), down 13.6%, and Acura Pharmaceuticals ( ACUR), down 12.2%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $101.56 billion and is part of the health care sector. The company has a P/E ratio of four, below the S&P 500 P/E ratio of 17.7. Shares are up 11.3% year to date as of the close of trading on Tuesday. Currently there are two analysts that rate Novo Nordisk A/S a buy, one analyst rates it a sell, and two rate it a hold.

TheStreet Ratings rates Novo Nordisk A/S as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value.

On the positive front, Osiris Therapeutics ( OSIR), up 35.3%, Vical Incorporated ( VICL), up 15.4%, Astex Pharmaceuticals ( ASTX), up 11.2%, and CytRx Corporation ( CYTR), up 10.3%, were all gainers within the drugs industry with Vertex Pharmaceuticals ( VRTX) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.